Form 4: Mineralys Therapeutics Director, Derek DiRocco, Acquires 22,000 Stock Options

Director Derek DiRocco acquired 22,000 stock options in Mineralys Therapeutics, Inc. on May 22, 2024.

Summary

• On May 22, 2024, Derek DiRocco, a director of Mineralys Therapeutics, Inc., acquired 22,000 stock options.
• The exercise price of these options is $12.52.
• The options vest in 12 substantially equal monthly installments starting June 22, 2024.
• If the next annual meeting of stockholders occurs before May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting.
• Following the transaction, DiRocco directly owns 22,000 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard transaction reporting. The acquisition of stock options by a director is generally viewed positively, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the stock options suggests a long-term commitment from the director to the company's success.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The acquisition of stock options by a director could positively influence shareholder sentiment.

Key Dates